First Fill Buy Downs: Maximizing Return in the Face of Prior Authorization

There is no question that prior authorization (PA) requirements around prescribed branded and specialty ...

The Unintended Consequences Behind Gilead’s Remdesivir Pricing Announcement

At the end of June, Gilead announced its long-awaited pricing strategy for remdesivir, which ...

The Ever-Evolving Remote Patient Monitoring Reimbursement Landscape

The urgency of the COVID-19 pandemic has illustrated how essential telehealth services are to ...

Value-Based Healthcare—Demonstrating Value in an Era of Increased Scrutiny and Accountability

Value-based care, value-based contracting, outcomes-based contracting, risk-based contracting—the emergence of these strategies have left ...

Pharma Must Demonstrate Better Outcomes for Pay-Per-Performance

In the dramatically changing pharma industry, one key trend that overlays providers of care, ...

COVID-19: How are Payers Managing These Days?

If there’s one thing we know about payers, it’s they hate surprises. That’s why ...

Is Significant Change on the Horizon for Payers, Pricing, and Pharma?

Thanks to the 2020 presidential election, pharma companies can expect plenty of talk from ...

Two Key Questions About Payer Strategies in 2020

PM360 asked experts within market access strategies whether pricing regulation will impact 2020 and ...